SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on November 16, 2012, covering events occurring on November 14 and 15, 2012. The filing discloses the entry into material definitive agreements regarding a public offering of common stock. Note: The request metadata referenced "Riot Platforms, Inc."; however, the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
- Offering Size: 1,946,000 shares of common stock.
- Public Offering Price: $2.10 per share.
- Underwriting Price: $1.95 per share.
- Expected Net Proceeds: Approximately $3.7 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to an additional 291,900 shares at the same price.
- Debt and Liquidity: The filing text does not provide specific values for existing debt, cash flow, or liquidity ratios outside of the expected proceeds from this offering.
Material Changes
The primary material change is the execution of two underwriting agreements with Aegis Capital Corp. as the representative. This represents a significant capital raise event intended to increase the company's cash position. The closing of the offering was expected on November 20, 2012, subject to customary conditions.
Outlook, Risks, and Unusual Items
- Management Commentary: The company issued a press release announcing the pricing of the offering.
- Lock-Up Provisions: All officers and directors have agreed not to sell, transfer, or dispose of company securities for a 90-day period following November 15, 2012.
- Risks and Contingencies: The offering is subject to customary closing conditions. The agreements include standard representations, warranties, and indemnification provisions.
- Unusual Items: None reported beyond the standard terms of a firm commitment underwritten public offering.
Investor Verification Checklist
- Verify the final closing date of the offering (expected November 20, 2012) and whether the over-allotment option was exercised.
- Confirm the actual net proceeds received versus the estimated $3.7 million.
- Review the attached Underwriting Agreements (Exhibits 1.1 and 1.2) for specific covenants and indemnification details.
- Monitor the 90-day lock-up expiration for potential selling pressure from insiders.
- Check subsequent filings for the use of proceeds and impact on the company's balance sheet.